文献速递肝病

慢加急性肝衰竭患者肝移植后的生存结局:一项前瞻性研究

Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study.
PubMed 文献 · J Hepatol · 2026-09-30

该前瞻性研究纳入全球63个肝移植中心的失代偿期肝硬化患者(伴或不伴ACLF 1-3级),2021-2023年入组并随访1年;同时前瞻性随访被拒绝肝移植的ACLF-2或ACLF-3患者。结果显示被拒绝移植的ACLF-2和ACLF-3患者1年死亡率分别达73%和88%,而移植后ACLF-3、ACLF-2、ACLF-1及无ACLF患者的非再移植病死率分别为21%、10.5%、10%和9%;ACLF-3且5-6个器官衰竭者移植后病死率高达42%。

要点

  • 被拒绝肝移植的ACLF-2和ACLF-3患者1年死亡率分别达73%和88%。
  • 移植后非再移植病死率:ACLF-3为21%,ACLF-2为10.5%,ACLF-1为10%,无ACLF为9%。
  • ACLF-3且5-6个器官衰竭者移植后病死率42%,提示该人群慎行常规移植。

核心结论

  • 严重ACLF患者接受肝移植的生存结局明显优于被拒绝移植者。
  • 5或6个器官衰竭者移植后死亡风险高,提示该人群不宜常规行肝移植。

研究设计与样本

  • 前瞻性研究,2021-2023年全球63个肝移植中心入组失代偿期肝硬化伴或不伴ACLF(1-3级)成人患者,随访1年。
  • 被拒绝肝移植的ACLF-2或ACLF-3患者也前瞻性随访1年。

主要发现

  • 被拒绝移植的144例患者中,ACLF-2者73%、ACLF-3者88%在1年内死亡。
  • 612例移植患者中,2%再移植,12%在1年内死亡。
  • 移植后非再移植病死率:ACLF-3为21%(5或6个器官衰竭时为42%),ACLF-2为10.5%,ACLF-1为10%,无ACLF为9%。
  • ACLF-3患者移植后ICU住院时间更长,但普通病房住院时间、再入院率和长期肾脏替代治疗需求相似。
  • 多变量分析中,移植后死亡风险较高的因素为在亚洲( vs 欧洲或北美)移植或在移植时存在ACLF-3( vs 无ACLF)。

关键数值与推荐

  • 被拒绝移植的ACLF-2患者1年死亡率为73%,ACLF-3患者为88%。
  • 移植后非再移植病死率:ACLF-3为21%,ACLF-2为10.5%,ACLF-1为10%,无ACLF为9%。
  • ACLF-3且5或6个器官衰竭者移植后病死率为42%。
  • 移植后死亡风险:亚洲 vs 欧洲或北美较高;ACLF-3 vs 无ACLF较高;ACLF-2 vs 无ACLF相似;亚洲 vs 拉丁美洲相似。

临床怎么用

  • 对ACLF-2或ACLF-3患者,肝移植可显著改善生存,不应仅因ACLF分级而拒绝移植。
  • ACLF-3且5或6个器官衰竭者移植后死亡风险高,需谨慎评估是否常规行肝移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of liver transplantation (LT) on mortality among patients with advanced cirrhosis who have two organ failures (acute-on-chronic liver failure-2 [ACLF-2]) or ≥ three organ failures (ACLF-3) is unclear. METHODS: Adults with decompensated cirrhosis with or without ACLF (grades 1-3), undergoing LT at 63 liver transplant centers worldwide were prospectively enrolled between 2021 and 2023 and followed for one year. Patients with ACLF-2 or ACLF-3 who were declined for LT were also prospectively followed for one year. RESULTS: Among the 144 patients declined for LT, 73% of those included with ACLF-2 and 88% of those with ACLF-3 died within 1 year. Of the 612 transplanted patients, 2% were re-transplanted and 12% died during the year. According to ACLF status at LT, the case-fatality rate without re-transplantation was 21% with ACLF-3 (42% when patients had five or six organ failures), 10.5% with ACLF-2, 10% with ACLF-1 (one organ failure), and 9% without ACLF. During the post-LT period, ACLF-3 patients experienced longer intensive care stay but similar ward stay, readmission rate and requirement for long-term renal replacement therapy. In time-to-event multivariable analyses, variables that were associated with higher post-LT mortality were being transplanted in Asia (vs. Europe or North America) or having ACLF-3 at LT (vs. no ACLF). The risk of dying after LT was similar in Asia vs. Latin America or with ACLF-2 vs. no ACLF. CONCLUSIONS: Patients with severe ACLF who underwent LT showed markedly better survival outcomes than those who were declined. Patients with five or six organ failures had high risk of post-LT death cautioning against routine LT in this population. CLINICAL TRIAL NUMBER: ClinicalTrials.gov number, NCT04613921.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Gustot T, Bernal W, Fernández J, et al. Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study. J Hepatol. 2026. PMID: 42822699. doi:10.1016/j.jhep.2026.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。